Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma

Annals of Surgery

Volumn 259, Issue 5, 2014, Pages 861-872

  Sahani, Dushyant V ^a   Bajwa, Mohammad Ali ^a   Andrabi, Yasir ^a   Bajpai, Surabhi ^a   Cusack, James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

colorectal cancer; imaging; liver metastases; treatment options; treatment response monitoring

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; ECHOGRAPHY; FATTY LIVER; HUMAN; LIVER METASTASIS; LIVER WEIGHT; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; EARLY DIAGNOSIS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODAL IMAGING; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84899479309     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000525     Document Type: Review

References (119)

1. American Cancer Society. Cancer Facts & Figures 2011-2013. Available at: http://www.cancer.org/research/cancerfactsstatistics/index. Accessed January 21, 2014.
2. Taylor I. Adjuvant chemotherapy after resection of liver metastases from colorectal cancer. Eur J Cancer. 2008; 44: 1198-1201.
3. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244: 254-259.
4. Fong Y, Fortner J, Sun R, et al. Clinical score for predicting recurrence after resection for metastatic colorectal cancer analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318.
5. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MRI, PET): a meta-analysis. Radiology. 2002; 224: 748-756.
6. Tzeng CW, Aloia TA. Colorectal liver metastases. J Gastrointest Surg. 2013; 17: 195-201.
7. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010; 3: 19-31.
8. Kane RA, Hughes LA, Cua EJ, et al. The impact of intraoperative ultrasonography on surgery for liver neoplasms. J Ultrasound Med. 1994; 13: 1-6.
9. SolomonMJ, StephenMS, Gallinger S, et al. Does intraoperative ultrasonography change surgical decision making during liver resection? Am J Surg. 1994; 168: 307-310.
10. Cervone A, Sardi A, Conaway GL. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Ann Surg. 2000; 66: 611-615.
11. Lordan JT, Stenson KM, Karanjia ND. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg. Engl. 2011; 93: 246-249.
12. Sahani D, Kalva SP, Tanabe KK, et al. Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR imaging. Radiology. 2004; 232: 810-814.
13. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what role? Radiology. 2010; 257: 24-39.
14. Strobel D, Bernatik T, Blank W, et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (≤20 mm) and subcentimetric (≤10mm) focal liver lesions in comparison with histology. Results of theDEGUMmulticenter trial. Ultraschall Med. 2011; 32: 593-597.
15. Salvatore V, Borghi A, Piscaglia F. Contrast-enhanced ultrasound for liver imaging: recent advances. Curr Pharm Des. 2012; 18: 2236-2252.
16. Loss M, Schneider J, Uller W, et al. Intraoperative high resolution linear contrast enhanced ultrasound (IOUS) for detection of microvascularization of malignant liver lesions before surgery or radio-frequency ablation. Clin Hemorheol Microcirc. 2012; 50: 65-77.
17. Ruzzenente A, Conci S, Iacono C, et al. Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy. J Gastrointest Surg. 2013; 17: 281-287.
18. Schulz A, Dormagen JB, Drolsum A, et al. Impact of contrast-enhanced intraoperative ultrasound on operation strategy in case of colorectal liver metastasis. Acta Radiol. 2012; 53: 1081-1087.
19. Rappeport ED, Loft A. Livermetastases from colorectal cancer: imaging with super paramagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging. 2007; 32: 624-634.
20. Martinez L, Puig I, Valls C. Colorectal livermetastases: radiological diagnosis and staging. Eur J Surg. Oncol. 2007; 33: S5-S16
21. Reggea D, Campanellaa D, Anselmetti GC, et al. Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. Clin Radiol. 2006; 61: 338-347.
22. Schima W, Kulinna C, Langenberger H, et al. Liver metastases of colorectal cancer: US, CT, or MR? Cancer Imaging. 2005; 5(spec No A): S149-156.
23. Sahani DV, Krishnamurthy SK, Kalva S, et al. Multidetector-row computed tomography angiography for planning intra-arterial chemotherapy pump placement in patients with colorectal metastases to the liver. J Comput Assist Tomogr. 2004; 28: 478-484.
24. Hekimoglu K, Ustundag Y, Dusak A, et al. Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging. Eur J Radiol. 2011; 77: 468-472.
25. Wiering B, Ruers TJ, Krabbe PF, et al. Comparison of multiphase CT, FDGPET and intra-operative ultrasound in patientswith colorectal livermetastases selected for surgery. Ann Surg. Oncol. 2007; 14: 818-826.
26. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006; 24: 3939-3945.
27. Kulemann V, SchimaW, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011; 79: e1-e6.
28. Berger-Kulemann V, Schima W, Baroud S, et al. Gadoxetic acid-enhanced 3.0-TMR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg. Oncol. 2012; 38: 670-676.
29. Rappeport ED, Loft A, Berthelsen AK, et al. Contrast-enhanced FDGPET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 2007; 48: 369-378.
30. Mueller GC, Hussain HK, Carlos RC, et al. Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. Am J Roentgenol. 2003; 180: 673-680.
31. Robinson E, Babb J, Chandarana H, et al. Dual source dual energy MDCT: comparison of 80 kVp and weighted average 120 kVp data for conspicuity of hypo-vascular liver metastases. Invest Radiol. 2010; 45: 413-418.
32. Sahani D, Kalva S, Fischman A, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liverMRI and whole-body FDG PET. Am J Roentgenol. 2005; 185: 239-246.
33. Chan VO, Das JP, Gerstenmaier JF, et al. Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(R))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre. Ir J Med Sci. 2012; 181: 499-509.
34. Ward J, Robinson PJ, Guthrie JA, et al. Livermetastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO- enhanced MR imaging. Radiology. 2005; 237: 170-180.
35. Holalkere NS, Sahani DV, Blake MA, et al. Characterization of small liver lesion: added role ofMRafter MDCT. JComput Assist Tomogr. 2006; 30: 591-596.
36. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18- fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007; 11: 472-478
37. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012; 57: 421-429.
38. Jeong HT, Kim MJ, Park MS, et al. Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phaseMRimaging. J Magn Reson Imaging. 2012; 35: 635-643.
39. Bennett CL, Qureshi ZP, Sartor AO, et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012; 5: 82-88.
40. Eiber M, Fingerle AA, Brügel M, et al. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012; 81: 683-691.
41. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology. 2008; 246: 812-822.
42. Kenis C, Deckers F, De Foer B, et al. Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a standalone sequence? Eur J Radiol. 2012; 81: 1016-1023.
43. Macera A, Lario C, PetracchiniM, et al. Staging of colorectal livermetastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol. 2013; 23: 739-747.
44. Tajima T, Akahane M, Takao H, et al. Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases? Jpn J Radiol. 2012; 30: 648-658.
45. Koh DM, Collins DJ, Wallace T, et al. Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol. 2012; 85: 980-989.
46. Chung WS, Kim MJ, Chung YE, et al. Comparison of gadoxetic acidenhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging. 2011; 34: 345-353.
47. Kim YK, Lee MW, Lee WJ, et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤1.5 cm in diameter). Invest Radiol. 2012; 47: 159-166.
48. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res. 2002; 8: 759-767.
49. Adam R, Haas R, Wicherts D, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol. 2008; 26: 3672-3680.
50. Lian P, Hong JW, Ubukata H, et al. Myofibroblasts correlate with lymphatic microvessel density and lymph node metastasis in early-stage invasive colorectal carcinoma. Anticancer Res. 2005; 25: 2705-2712.
51. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007; 188: 1622-1635.
52. Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imagingwith background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008; 18: 1937-1952.
53. Papathanassiou D, Bruna-Muraille C, Liehn JC, et al. Positron emission tomography in oncology: present and future of PET and PET/CT. Crit Rev Oncol Hematol. 2009; 72: 239-254.
54. Mainenti PP, Mancini M, Mainolfi C, et al. Detection of colorectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5-Tesla MR with extracellular and reticuloendothelial cell-specific contrast agents. Abdom Imaging. 2010; 35: 511-521.
55. Cantwell CP, Setty BN, Holalkere N, et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr. 2008; 32: 738-744.
56. Maas M, Rutten IJ, Nelemans PJ, et al. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011; 38: 1560-1571.
57. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D- glucose in recurrent colorectal cancer. J Clin Oncol. 1999; 17: 894-901.
58. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996; 131: 703-707.
59. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg. Oncol. 1997; 4: 613-620.
60. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997; 38: 1196-1201.
61. Ruers TJM, Wiering B, Joost R, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med. 2009; 50: 1036-1041.
62. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004; 31: 932-939.
63. Coenegrachts K, Geeter FD, Beek L, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol. 2009; 19: 370-379.
64. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005; 23: 8713-8716.
65. Nahas CS, Akhurst T, Yeung H, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg. Oncol. 2008; 15: 704-711.
66. vanKessel CS, Buckens CF, van den BoschMA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg. Oncol. 2012; 19: 2805-2813.
67. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010; 51: 692-699.
68. Catalano OA, Singh AH, Uppot RN, et al. Vascular and biliary variants in the liver: implications for liver surgery. Radiographics. 2008; 28: 359-378.
69. Buchbender C, Heusner TA, Lauenstein TC, et al. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012; 53: 928-938.
70. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2008; 2: CD006039.
71. Oliva MR, Saini S. Liver cancer imaging: role of CT, MRI, US, and PET. Cancer Imaging. 2004; 4 Spec No A: S42-S46.
72. Alsina J, Choti MA. Liver-directed therapies in colorectal cancer. Semin Oncol. 2011; 38: 561-567.
73. Valls C, Andía E, Sánchez A, et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology. 2001; 218: 55-60.
74. Inaba Y, Arai Y, Kanematsu M, et al. revealing hepatic metastases from colorectal cancer, Value of combined helical CT during arterial portography and CT hepatic arteriography with a unified CT and angiography system. Am J Roentgenol. 2000; 174: 955-961.
75. Sahani D, Saini S, Pena C, et al. Using multidetector CT for preoperative vascular evaluation of liver neoplasms: technique and results. Am J Roentgenol. 2002; 179: 53-59.
76. Wigmore SJ, Redhead DN, Yan XJ, et al. Virtual hepatic resection using three-dimensional reconstruction of helical computed tomography angioportograms. Ann Surg. 2001; 233: 221-226.
77. Lee SG, Hwang S. How I do it: assessment of hepatic functional reserve for indication of hepatic resection. J Hepatobiliary Pancreat Surg. 2005; 12: 38-43.
78. Lehmann K, Rickenbacher A, Weber A, et al. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012; 255: 237-247.
79. Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg. Oncol. 2006; 13: 1261-1268.
80. Tarazov PG, Granov DA, Sergeev VI, et al. Preoperative portal vein embolization for liver malignancies. Hepatogastroenterology. 2006; 53: 566-570.
81. WichertsDA, deHaas RJ, Andreani P, et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg. 2010; 97: 240-250.
82. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012; 255: 405-414.
83. Hiroshige S, Shimada M, Harada N, et al. Accurate preoperative estimation of liver-graft volumetry using three-dimensional computed tomography. Transplantation. 2003; 75: 1561-1564.
84. Hamer OW, Aguirre DA, Casola G, et al. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006; 26: 1637-1653.
85. CowinGJ, Jonsson JR, Bauer JD, et al.Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. JMagn Reson Imaging. 2008; 28: 937-945.
86. Urdzik J, Bjerner T, Wanders A, et al. The value of preoperative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. J Hepatol. 2012; 56: 640-646.
87. Lorenz M, Hochmuth K, Muller HH. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. N Engl J Med. 2000; 342: 1525-1526.
88. Seront E, Van den Eynde M. Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases? Clin Colorectal Cancer. 2012; 11: 177-184.
89. deBaere T, Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging. 2011; 36: 661-670.
90. Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period [published online ahead of print August 19, 2013]. Int J Cancer. 2013.
91. Aliberti C, Tilli M, Benea G, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecaneluting beads: preliminary results. Anticancer Res. 2006; 26: 3793-3795.
92. Callahan MK, Kemeny NE. Implanted hepatic arterial infusion pumps. Cancer J. 2010; 16: 142-149.
93. Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: S62-S73.
94. Jiao LR, Szysko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg. Oncol. 2007; 33: 597-602.
95. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010; 16: 163-175.
96. LauWY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012; 82: 401-407.
97. Morgan B, Kennedy AS, Lewington V, et al. Intra-arterial brachytherapy of hepatic malignancies: watch the flow. Nat Rev Clin Oncol. 2011; 8: 115-120.
98. Swaminath A, Dawson LA. Emerging role of radiotherapy in themanagement of liver metastases. Cancer J. 2010; 16: 150-155.
99. Tao C, Yang LX. Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy. Anticancer Res. 2012; 32: 649-655.
100. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27: 1572-1578.
101. Kress MS, Collins BT, Collins SP, et al. Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes. Front Oncol. 2012; 2: 8.
102. Jakobs TF, Hoffmann RT, Trumm C, et al. Radiofrequency ablation of colorectal liver metastases: midterm results in 68 patients. Anticancer Res. 2006; 26: 671-680.
103. Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol. 2008; 19: 712-717.
104. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010; 16: 111-117.
105. Thomas JV, Naguib NN, Eichler K, et al. Volumetric evaluation of liver metastases after thermal ablation: long-term results following MR-guided laser-induced thermotherapy. Radiology. 2008; 249: 865-871.
106. Ninomiya T, Seo Y, Yano Y, et al. Evaluation of the therapeutic effect using MD-CT immediately after RFA for HCC. Hepatogastroenterology. 2006; 53: 558-560.
107. Nghiem HV, Francis IR, Fontana R, et al. Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy. Curr Probl Diagn Radiol. 2002; 31: 105-111.
108. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002; 20: 4453-4458.
109. Barker DW, Zagoria RJ, Morton KA, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. Am J Roentgenol. 2005; 184: 1096-1102.
110. Bilchik AJ, Poston G, Adam R, et al. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol. 2008; 26: 5320-5321.
111. Eisenhauer EA, Therasse P, Bogaertsetal J. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Canc. 2009; 45: 228-247.
112. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008; 28: 329-344.
113. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
114. Kalkmann J, Zeile M, Antoch G, et al. Consensus report on the radiological management of patientswith gastrointestinal stromal tumours (GIST): recommendations of the German GIST imaging working group. Cancer Imaging. 2012; 12: 126-135.
115. Zhu AX, Holalkere NS, Muzikansky A, et al. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008; 13: 120-125.
116. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology. 2005; 234: 785-792.
117. De Bruyne S, Van Damme N, Smeets P, et al. Value of DCE-MRI and FDGPET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012; 106: 1926- 1933.
118. Stinauer MA, Diot Q, Westerly DC, et al. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys. 2012; 83: e613-e618.
119. Zerizer I, Al-Nahhas A, Towey D, et al. The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012; 39: 1391-1399.